ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Enhancing the miRNA Detection Sensitivity of DNA Origami Book Biosensors Using Lock Modifications and a Polymer Additive.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From Blueprint to Breakthrough: How Far Can We Fold DNA Origami for Nano-Enabled Technologies?JACS Au · 2026Review
- Dynamic DNA Nanomachines for Biosensing and Drug Delivery.Sensors (Basel, Switzerland) · 2026Review
- Enhancing the miRNA Detection Sensitivity of DNA Origami Book Biosensors Using Lock Modifications and a Polymer Additive.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
DNA origami-based biosensors provide a powerful and programmable platform for sensitive and specific molecular diagnostics. In this study, a dynamic DNA origami book biosensor is validated for direct detection of microRNA21 (miR-21) in complex biological fluids, including human serum and plasma. Two optical readouts are engineered and tested: Förster resonance energy transfer (FRET) and fluorescence quenching using precisely arranged donor-acceptor fluorophore pairs. To improve sensitivity, detection occurs under varied conditions, including modifications to the lock mechanism (fluorine-modified bases and locked nucleic acid) and the addition of a biocompatible polymer, diethylene glycol (DEG). The biosensor maintains specificity in spiked serum, plasma, and clinical plasma samples from breast cancer patients. Single origami nanostructure detection experiments show that target miRNAs are identified within 10 min, with limits of detection (LoD) of 0.69 pm in buffer with LNA, 8.86 pm in 100% serum, and 23.24 pm in 100% plasma, without enzymatic amplification. Importantly, simultaneous detection of miR-21 and miR-7a in clinical plasma samples is demonstrated, underscoring the platform's potential for personalized diagnostics and liquid biopsy applications. These results show that tuning the lock mechanism and adding polymers enhances sensitivity and enables adaptable performance, advancing nanotechnology-based biomarker profiling, including diverse microRNA detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.